A controversy has been brewing under the surface for several months in the genetic testing world. Namely, will BRCA carriers with ovarian cancer be forced to undergo BRCA testing a second time, at more than $4,000 a pop, in order to qualify for a new drug called...
The American College of Obstetricians and Gynecologists (ACOG) recently published a committee opinion for women of population risk to develop ovarian cancer. ACOG recommends that average risk women who are having gynecological surgery, such as removal of their uterus...
Last week in Genetic Privacy Part 1, we discussed the potential harm done when a patient chooses not to share her data with other family members. Such arguments, and the argument that widely sharing genetic data would advance scientific research, have made some...
The debate about who should have access to genetic test results has been argued for decades. There are many factors to consider, including: individual rights, the rights of family members, medical liability, insurance issues, and the betterment of scientific research....
It is well-known that women who carry a mutation in BRCA1 or BRCA2 are at high risk to develop breast cancer (50-85% lifetime risk) and ovarian cancer (15-60% lifetime risk). Because the screening options for ovarian cancer (transvaginal ultrasound, the blood test...
